| Outcome Measures: |
Primary: Subjects included in the composite endpoint of cardiovascular death, myocardial infarction or ischemic stroke (time to first or recurrent event)., Data will be derived from 3 monthly telephone follow-up and 6monthly physical site visits and events are documented in eCRF, Up to 3 years | Secondary: Subjects included in the composite endpoint of all-cause death or hospitalization for unstable angina (time to first or recurrent event)., Data will be derived from 3 monthly telephone follow-up and 6monthly physical site visits and events are documented in eCRF, Up to 3 years | Other: Safety and tolerability will be assessed from overall adverse events, serious adverse events, adverse events of special interest, The assessment will include an evaluation of the incidence of adjudicated hyperkalemia, diabetic ketoacidosis, thromboembolic event, genital infections, bone fractures,amputation, liver injury etc.Data will be derived from 3 monthly telephone follow-up and 6monthly physical site visits and events are documented in eCRF, Up to 3 years
|
